Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
Identifieur interne : 000F73 ( Istex/Corpus ); précédent : 000F72; suivant : 000F74Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
Auteurs : Richard M. Camicioli ; Thomas P. Bouchard ; Martin J. SomervilleSource :
- Movement Disorders [ 0885-3185 ] ; 2009-01-30.
English descriptors
- KwdEn :
Abstract
Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22227
Links to Exploration step
ISTEX:8D8D4721F3927D26EFD2C116CBEB0F3684705A37Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><author><name sortKey="Camicioli, Richard M" sort="Camicioli, Richard M" uniqKey="Camicioli R" first="Richard M." last="Camicioli">Richard M. Camicioli</name><affiliation><mods:affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</mods:affiliation></affiliation></author><author><name sortKey="Bouchard, Thomas P" sort="Bouchard, Thomas P" uniqKey="Bouchard T" first="Thomas P." last="Bouchard">Thomas P. Bouchard</name><affiliation><mods:affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</mods:affiliation></affiliation></author><author><name sortKey="Somerville, Martin J" sort="Somerville, Martin J" uniqKey="Somerville M" first="Martin J." last="Somerville">Martin J. Somerville</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8D8D4721F3927D26EFD2C116CBEB0F3684705A37</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22227</idno><idno type="url">https://api.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F73</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><author><name sortKey="Camicioli, Richard M" sort="Camicioli, Richard M" uniqKey="Camicioli R" first="Richard M." last="Camicioli">Richard M. Camicioli</name><affiliation><mods:affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</mods:affiliation></affiliation></author><author><name sortKey="Bouchard, Thomas P" sort="Bouchard, Thomas P" uniqKey="Bouchard T" first="Thomas P." last="Bouchard">Thomas P. Bouchard</name><affiliation><mods:affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</mods:affiliation></affiliation></author><author><name sortKey="Somerville, Martin J" sort="Somerville, Martin J" uniqKey="Somerville M" first="Martin J." last="Somerville">Martin J. Somerville</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-30">2009-01-30</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="176">176</biblScope><biblScope unit="page" to="182">182</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8D8D4721F3927D26EFD2C116CBEB0F3684705A37</idno><idno type="DOI">10.1002/mds.22227</idno><idno type="ArticleID">MDS22227</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B‐vitamins</term><term>MTHFR</term><term>Parkinson's disease</term><term>homocysteine</term><term>mental status</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Richard M. Camicioli MD</name><affiliations><json:string>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</json:string></affiliations></json:item><json:item><name>Thomas P. Bouchard BSc</name><affiliations><json:string>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</json:string></affiliations></json:item><json:item><name>Martin J. Somerville PhD</name><affiliations><json:string>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>homocysteine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MTHFR</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>B‐vitamins</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mental status</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P > 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P > 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>6.647</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1386</abstractCharCount><pdfWordCount>4067</pdfWordCount><pdfCharCount>25866</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>215</abstractWordCount></qualityIndicators><title>Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><genre><json:string>Serial article</json:string></genre><host><volume>24</volume><pages><total>7</total><last>182</last><first>176</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22227</json:string></doi><id>8D8D4721F3927D26EFD2C116CBEB0F3684705A37</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note><note>Canadian Institute for Health Research (CIHR)</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title><author><persName><forename type="first">Richard M.</forename><surname>Camicioli</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: E223 Glenrose Rehabilitation Hospital, 10230 111th Avenue, Edmonton, Alberta T5G 0B7</p></note><affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</affiliation></author><author><persName><forename type="first">Thomas P.</forename><surname>Bouchard</surname><roleName type="degree">BSc</roleName></persName><affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</affiliation></author><author><persName><forename type="first">Martin J.</forename><surname>Somerville</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-30"></date><biblScope unit="vol">24</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="176">176</biblScope><biblScope unit="page" to="182">182</biblScope></imprint></monogr><idno type="istex">8D8D4721F3927D26EFD2C116CBEB0F3684705A37</idno><idno type="DOI">10.1002/mds.22227</idno><idno type="ArticleID">MDS22227</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>homocysteine</term></item><item><term>Parkinson's disease</term></item><item><term>MTHFR</term></item><item><term>B‐vitamins</term></item><item><term>mental status</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-04-23">Received</change><change when="2008-06-17">Registration</change><change when="2009-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/8D8D4721F3927D26EFD2C116CBEB0F3684705A37/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v24:2</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2009-01-30">30 January 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="30" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22227</doi><idGroup><id type="unit" value="MDS22227"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-04-23"></event><event type="manuscriptRevised" date="2008-03-25"></event><event type="manuscriptAccepted" date="2008-06-17"></event><event type="publishedOnlineEarlyUnpaginated" date="2008-10-24"></event><event type="firstOnline" date="2008-10-24"></event><event type="publishedOnlineFinalForm" date="2009-01-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">176</numbering><numbering type="pageLast">182</numbering></numberingGroup><correspondenceTo>E223 Glenrose Rehabilitation Hospital, 10230 111th Avenue, Edmonton, Alberta T5G 0B7</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22227.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="38"></count><count type="wordTotal" number="4889"></count></countGroup><titleGroup><title type="main" xml:lang="en">Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients<link href="#fn1"></link></title><title type="short" xml:lang="en">Hcy is not Associated with Global Measures</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Richard M.</givenNames><familyName>Camicioli</familyName><degrees>MD</degrees></personName><contactDetails><email>rcamicio@ualberta.ca</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Thomas P.</givenNames><familyName>Bouchard</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Martin J.</givenNames><familyName>Somerville</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CA" type="organization"><unparsedAffiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="CA" type="organization"><unparsedAffiliation>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">homocysteine</keyword><keyword xml:id="kwd2">Parkinson's disease</keyword><keyword xml:id="kwd3">MTHFR</keyword><keyword xml:id="kwd4">B‐vitamins</keyword><keyword xml:id="kwd5">mental status</keyword></keywordGroup><fundingInfo><fundingAgency>Canadian Institute for Health Research (CIHR)</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Levodopa (<sc>L</sc>‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), <i>P</i> < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, <i>P</i> < 0.0005], folate level (R = 0.31, <i>P</i> = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, <i>P</i> = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Hcy is not Associated with Global Measures</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients</title></titleInfo><name type="personal"><namePart type="given">Richard M.</namePart><namePart type="family">Camicioli</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</affiliation><description>Correspondence: E223 Glenrose Rehabilitation Hospital, 10230 111th Avenue, Edmonton, Alberta T5G 0B7</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thomas P.</namePart><namePart type="family">Bouchard</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin J.</namePart><namePart type="family">Somerville</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-01-30</dateIssued><dateCaptured encoding="w3cdtf">2007-04-23</dateCaptured><dateValid encoding="w3cdtf">2008-06-17</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">38</extent><extent unit="words">4889</extent></physicalDescription><abstract lang="en">Levodopa (L‐dopa) treatment of Parkinson's disease (PD) is associated with elevated homocysteine (Hcy). To examine the relationship between Hcy, methylenetetrahydrofolate reductase polymorphisms (MTHFR: 677C/T; 1298A/C), and B‐vitamins in older PD patients and whether Hcy or MTHFR polymorphisms were associated with clinical measures. MTHFR polymorphisms, B‐vitamin intake, and blood concentrations of Hcy, vitamin B12 and folate, and creatinine were determined and compared between groups (PD and controls). The relationship of Hcy to clinical measures was examined in PD. Among 51 patients [30M/21F, mean age (SD): 71.5 (4.7)] and 50 controls [29M/21F, 71.5 (4.8)], Hcy was higher in PD [13.6 (3.8); controls: 10.5 (2.5), P < 0.0005]. Hcy was associated with B‐vitamin intake [F = 21.7, P < 0.0005], folate level (R = 0.31, P = 0.035), and the interaction of intake with MTHFR 677T (F = 5.2, P = 0.007), but not MTHFR 1298C genotype. Hcy did not correlate with global measures of cognition, mood, or parkinsonism in PD or with dyskinesias, fluctuations, or freezing. Higher vitamin B12 levels were associated with lower dyskinesia risk. Hcy was influenced by PD, MTHFR 677 genotype, and vitamin use, but not by the MTHFR 1298 genotype. There was no clear association with motor or cognitive measures, but dyskinesias were less likely with higher B12. © 2008 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><note type="funding">Canadian Institute for Health Research (CIHR)</note><subject lang="en"><genre>Keywords</genre><topic>homocysteine</topic><topic>Parkinson's disease</topic><topic>MTHFR</topic><topic>B‐vitamins</topic><topic>mental status</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>176</start><end>182</end><total>7</total></extent></part></relatedItem><identifier type="istex">8D8D4721F3927D26EFD2C116CBEB0F3684705A37</identifier><identifier type="DOI">10.1002/mds.22227</identifier><identifier type="ArticleID">MDS22227</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F73 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F73 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8D8D4721F3927D26EFD2C116CBEB0F3684705A37
|texte= Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients
}}
| This area was generated with Dilib version V0.6.23. |  |